# Clinical trials recruiting in Estonia: 84 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 84 trials recruiting or not yet recruiting with a site in Estonia, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Estonia: 84 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/estonia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 84
- Recruiting or not yet: 84
- Read on: November 19, 2026

## Trials

The 25 newest of 84, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 1, 2026 | NCT07851025 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced... | AstraZeneca | Phase 3 | Recruiting | Epithelial Ovarian Cancer | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851025) |
| September 29, 2026 | NCT07846111 | Safety and Feasibility of the INGA Sensor System for Fetal and Uterine Monitoring During Cervical Ripening | Aalto University | Not applicable | Not yet recruiting | Induced Labor, Cervical Ripening, Cervical Ripening and Induction of Labor, Balloon Catheter for Labor Induction | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846111) |
| September 18, 2026 | NCT07828769 | The Effect of Orofacial Myofunctional Therapy on Neuromuscular Outcomes and Orofacial Function in Children and Adolescents in Estonia | Tartu University Hospital | Not applicable | Not yet recruiting | Orofacial Myofunctional Disorders | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828769) |
| August 11, 2026 | NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple... | Odense University Hospital | Phase 2 | Not yet recruiting | Multiple Myeloma Progression | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757412) |
| May 28, 2026 | NCT07610356 | Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia | University of Tartu | Observational | Recruiting | Non-Occlusive Mesenteric Ischaemia (NOMI), Acute Mesenteric Ischemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610356) |
| May 13, 2026 | NCT07582562 | Risk Factors for Hypoparathyroidism Following Thyroidectomy | Tartu University Hospital | Observational | Recruiting | Post-Surgical Hypoparathyroidism | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582562) |
| May 11, 2026 | NCT07577570 | Calcium Replacement Therapy in Postoperative Hypoparathyroidism | Tartu University Hospital | Not applicable | Recruiting | Post-Thyroidectomy Hypoparathyroidism Treatment | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577570) |
| April 22, 2026 | NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian... | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 3 | Recruiting | Ovarian Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546500) |
| March 27, 2026 | NCT07497087 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Boehringer Ingelheim | Phase 3 | Recruiting | Systemic Sclerosis | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497087) |
| March 24, 2026 | NCT07491549 | The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity | University of Tartu | Not applicable | Recruiting | Chronic Pain | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491549) |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472517) |
| March 12, 2026 | NCT07466147 | The Effect of Playful Physiotherapy Intervention | University of Tartu | Not applicable | Recruiting | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466147) |
| February 27, 2026 | NCT07440225 | A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | EyeBiotech Ltd. | Phase 2/3 | Recruiting | Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration | 960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440225) |
| January 22, 2026 | NCT07359846 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Generate Biomedicines | Phase 3 | Recruiting | Severe Asthma | 786 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07359846) |
| December 23, 2025 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07299019) |
| December 17, 2025 | NCT07288489 | Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require... | VarmX B.V. | Phase 3 | Recruiting | Blood Loss, Surgical, Coagulation Disorder | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288489) |
| December 16, 2025 | NCT07286058 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | Takeda | Phase 3 | Recruiting | Psoriatic Arthritis | 1,182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286058) |
| December 11, 2025 | NCT07276490 | Central Haemodynamics and Pacing for AV Block | University of Tartu | Not applicable | Recruiting | Atrioventricular Block, Pacing Therapy, Right Ventricular Pacing, Conduction System Pacing | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276490) |
| November 21, 2025 | NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney... | Eli Lilly and Company | Phase 3 | Recruiting | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease | 7,140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241390) |
| November 19, 2025 | NCT07235462 | A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a... | Bayer | Observational | Recruiting | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235462) |
| November 6, 2025 | NCT07225504 | A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | Phase 3 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 1,275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225504) |
| November 3, 2025 | NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute... | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | Recruiting | Acute Myeloid Leukemia | 875 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223814) |
| September 29, 2025 | NCT07196501 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07196501) |
| September 24, 2025 | NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic... | Sanofi | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190209) |
| August 22, 2025 | NCT07136467 | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis... | AbbVie | Observational | Recruiting | Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa | 2,795 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136467) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Tartu University Hospital | Tartu | 28 |
| North Estonia Medical Centre Foundation | Tallinn | 10 |
| East Tallinn Central Hospital | Tallinn | 7 |
| North Estonia Medical Centre | Tallinn | 5 |
| University of Tartu | Tartu | 3 |
| Tartu University Hospital-Radiotherapy and oncology | Tartu | 2 |
| West Tallinn Central Hospital | Tallinn | 2 |
| North Estonia Medical Centre, Dept of Haematology | Tallinn | 2 |
| Tallinn Children´s Hospital, Dept of Paediatrics | Tallinn | 2 |
| North Estonia Medical Centre Foundation, Tallinn | Tallinn | 2 |
| Innomedica OU | Tallinn | 1 |
| Center for Clinical and Basic Research | Tallinn | 1 |
| Clinical Research Centre Ltd | Tartu | 1 |
| East-Tallinn Central Hospital | Tallinn | 1 |
| North Estonia Medical Centre /ID# 276933 | Tallinn | 1 |
| Tartu University Hospital /ID# 276932 | Tartu | 1 |
| Tartu University Hospital, Clinic of Dentistry | Tartu | 1 |
| Põhja-Eesti Regionaalhaigla | Tallinn | 1 |
| East Tallinn Central Hospital, Centre of Anaesthesiology and Intensive Care | Tallinn | 1 |
| North Estonia Medical Centre Foundation, Intensive Care Centre | Tallinn | 1 |
| Tartu University Hospital, Anesthesiology and Intensive Care Clinic | Tartu | 1 |
| Institute of Clinical Medicine | Tartu | 1 |
| Tartu University Hospital, Department of Gastroenterology | Tartu | 1 |
| East Tallinn Central Hospital-Pärnu road 104 | Tallinn | 1 |
| Confido Medical Centre | Tallinn | 1 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 6 |
| Phase 2/3 | 2 |
| Phase 3 | 37 |
| Phase 4 | 1 |
| Not applicable | 18 |
| Observational | 20 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Myeloid, Acute | 4 |
| COVID-19 | 3 |
| Chickenpox | 3 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 3 |
| Depression | 3 |
| Kidney Diseases | 3 |
| Multiple Myeloma | 3 |
| Multiple Sclerosis, Chronic Progressive | 3 |
| Community-Acquired Pneumonia | 2 |
| Pneumonia | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Renal Insufficiency | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Leukemia | 2 |
| Crohn Disease | 2 |
| Depressive Disorder, Major | 2 |
| Aortic Valve Stenosis | 2 |
| Heart Failure | 2 |
| Heart Valve Diseases | 2 |
| Neoplasms | 2 |
| Heart Diseases | 2 |
| Arthritis, Psoriatic | 1 |
| Respiratory Tract Diseases | 1 |
| Influenza, Human | 1 |
| Respiratory Tract Infections | 1 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Tartu | 9 |
| Tartu University Hospital | 6 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 4 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 3 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 2 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Tampere University Hospital | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| ETOP IBCSG Partners Foundation | 2 |
| Ceric Sàrl | 2 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 2 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 2 |
| Zenas BioPharma (USA), LLC | 2 |
| Meril Life Sciences Pvt. Ltd. | 2 |
| [Abbott Medical Devices](https://specstream.ai/data/clinical-trials/company/abbott-medical-devices) | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 2 |
| UMC Utrecht | 1 |
| University of Ulm | 1 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 1 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 1 |
| [Genzyme, a Sanofi Company](https://specstream.ai/data/clinical-trials/company/genzyme-a-sanofi-company) | 1 |
| IDEAYA Biosciences | 1 |
| EyeBiotech Ltd. | 1 |
| VarmX B.V. | 1 |
| Odense University Hospital | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cooking schools in the United States](https://specstream.ai/data/businesses/cooking-schools/united-states)
- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
- [E-commerce services in the United States](https://specstream.ai/data/businesses/e-commerce-services/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Farming services in the United States](https://specstream.ai/data/businesses/farming-services/united-states)
- [Footwear wholesalers in the United States](https://specstream.ai/data/businesses/footwear-wholesalers/united-states)
